Abstract
The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinoma.
Copyright © 2018 by the National Comprehensive Cancer Network.
Publication types
-
Practice Guideline
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / standards
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / analysis
-
Biomarkers, Tumor / genetics
-
Biomarkers, Tumor / metabolism
-
Carcinoma / diagnosis
-
Carcinoma / mortality
-
Carcinoma / pathology
-
Carcinoma / therapy*
-
Clinical Trials as Topic
-
Humans
-
Image-Guided Biopsy / methods
-
Image-Guided Biopsy / standards
-
Medical Oncology / standards*
-
Neoplasm Staging
-
Prognosis
-
Protein Kinase Inhibitors / standards
-
Protein Kinase Inhibitors / therapeutic use
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
-
Proto-Oncogene Proteins B-raf / genetics
-
Societies, Medical / standards
-
Thyroid Gland / diagnostic imaging
-
Thyroid Gland / pathology
-
Thyroid Gland / surgery
-
Thyroid Neoplasms / diagnosis
-
Thyroid Neoplasms / genetics
-
Thyroid Neoplasms / pathology
-
Thyroid Neoplasms / therapy*
-
Thyroidectomy / methods
-
Thyroidectomy / standards
-
Treatment Outcome
-
United States
Substances
-
Biomarkers, Tumor
-
Protein Kinase Inhibitors
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf